Your session is about to expire
← Back to Search
Carboplatin + Docetaxel for Breast Cancer (CADENCE Trial)
CADENCE Trial Summary
This trial tests whether combining two cancer drugs is effective in treating patients with a certain type of breast cancer.
CADENCE Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCADENCE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2014 Phase 4 trial • 32 Patients • NCT01301729CADENCE Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have any severe illnesses or social situations that would stop me from following the study's requirements.My breast cancer is in multiple spots, all are estrogen and HER2 negative.I have a breast lump at least 2cm big, confirmed by imaging.My blood tests show normal organ function and healthy blood cell counts.I have not had cancer, except for certain skin cancers or cervical pre-cancer, in the last 5 years.My condition is inflammatory breast cancer.My cancer is at stage IV.I am allergic to medications similar to docetaxel or carboplatin.I have tested positive for HIV, HCV, or HBV.I have cancer in both breasts or cancer on one side and non-invasive cancer on the other.I am 18 years old or older.My breast cancer is not driven by estrogen or HER2, but may be slightly progesterone receptor positive.My breast tumor is at least 2 cm big.I am willing to use birth control, have a negative pregnancy test, and follow study rules.I have been diagnosed with invasive breast cancer.I have not had any breast cancer treatment in the last 5 years.
- Group 1: Docetaxel/Carboplatin
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What have physicians employed Docetaxel to address in their patients?
"Docetaxel is commonly prescribed for melanoma, but also has proven efficacy in treating head cancer, soft tissue sarcoma (STS), and non-Hodgkin lymphomas."
Is Docetaxel a viable option for patients due to its safety profile?
"Our internal assessment of docetaxel's safety is a 2, as there are some data that attest to its security but no studies regarding the drug's efficacy."
Are there still openings for participants in this experiment?
"As the trial was last updated on April 6th 2022, this research is no longer searching for volunteers. However, there are currently 2596 studies looking to recruit patients with breast cancer and 962 studies recruiting participants for Docetaxel treatment."
What is the maximum cohort size of this experiment?
"Unfortunately, this specific trial has concluded its recruitment process. It was initially announced on November 1st 2015 and the last update occurred April 6th 2022. However, if you're searching for alternatives involving breast cancer there are 2596 trials currently enrolling patients and 962 studies that utilize Docetaxel as a form of treatment."
Share this study with friends
Copy Link
Messenger